Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that iontophoresis significantly increased folicular delivery of minoxidil sulfate and sustained release when combined with chitosan microparticles, suggesting potential to reduce application frequency for treating androgenic alopecia.

This review examines the use of apremilast for non-FDA-approved dermatological conditions, noting varied efficacy but a favorable safety profile compared to conventional treatments.

In this study conducted at a tertiary care hospital in Karachi, oral Apremilast significantly reduced the severity of alopecia areata, shown by a notable decrease in SALT Scores over 12 weeks, suggesting it may be an effective alternative treatment option for this condition.

This case report documents successful virilization, including penile length increase, in a boy with partial androgen insensitivity syndrome using high-dose testosterone combined with anastrozole.

This animal study observed that treatment with the S1PR modulator NXC736 significantly reduced lesion area and CD8+ T cell infiltration in mice with alopecia areata, suggesting its potential as a promising therapy for the condition.

This study examined FAERS data and found an increasing trend in alopecia areata cases, with monoclonal antibodies most frequently linked to the condition.

This article reviews multiple treatments for alopecia areata, highlighting their variable efficacy and safety without any being curative; it reports no new clinical findings.

Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

This case report describes a 6-year-old girl diagnosed with monilethrix despite no familial history and treated with a topical minoxidil trial.

This study found that clove oil nanoemulsion hair serum effectively promoted hair growth, suggesting it may be a potential treatment for alopecia areata.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.

This review discusses Alopecia X in plush-coated dogs, noting that while treatments like melatonin and laser therapy have shown promise, the condition is generally considered a cosmetic issue without the need for therapy.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

This article presents a collection of interdisciplinary studies by Brazilian researchers that address various societal issues to contribute to the nation's social and scientific development; it reports no new results.

This case report describes an eight-year-old Kashmiri boy diagnosed with monilethrix, a rare genetic hair disorder, characterized by a beaded appearance and fragility of the hair shaft.

In this study, a 15-year-old male with alopecia areata universalis showed significant hair regrowth after an 8-month combination therapy, suggesting that comprehensive treatment, including antiviral, corticosteroid, and LED therapy, may be effective albeit long-term for managing this condition.

This study found that applying a 1% cetirizine solution daily for 16 weeks resulted in a statistically significant increase in hair count among men with androgenetic alopecia, although improvements in global photographs were less pronounced, highlighting the need for larger studies to confirm these findings.

This study found that oral Janus kinase inhibitors were effective in treating alopecia areata, with a clinical response rate of 48.3%, though further research is needed to assess long-term effects.

This case study describes a successful treatment of androgenetic alopecia in a 34-year-old man through a comprehensive program involving low-dose minoxidil, without finasteride, resulting in significant hair growth improvements.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

Azathioprine treatment led to rapid hair regrowth in a woman with alopecia universalis.

This case report from this study demonstrates the potential of treating severe alopecia areata with a combination of microneedling, minoxidil, desoximetasone, and methylprednisolone, noting initial hair regrowth after 14 days but emphasizing the need for further research to confirm long-term efficacy and safety.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.